Literature DB >> 22909335

Genotype-phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone and/or frontotemporal dementia.

S G Mehta1, M Khare, R Ramani, G D J Watts, M Simon, K E Osann, S Donkervoort, E Dec, A Nalbandian, J Platt, M Pasquali, A Wang, T Mozaffar, C D Smith, V E Kimonis.   

Abstract

Valosin containing protein (VCP) disease associated with inclusion body myopathy, Paget disease of the bone and frontotemporal dementia is a progressive autosomal dominant disorder caused by mutations in Valosin containing protein gene. To establish genotype-phenotype correlations we analyzed clinical and biochemical markers from a database of 190 members in 27 families harboring 10 missense mutations. Individuals were grouped into three categories: symptomatic, presymptomatic carriers and noncarriers. The symptomatic families were further divided into ten groups based on their VCP mutations. There was marked intra and inter-familial variation; and significant genotype-phenotype correlations were difficult to establish because of small numbers. Nevertheless when comparing the two most common mutations, R155C mutation was found to be more severe, with an earlier onset of myopathy and Paget (p = 0.03). Survival analysis of all subjects revealed an average life span after diagnosis of myopathy and Paget of 18 and 19 years respectively, and after dementia only 6 years. R155C had a reduced survival compared to the R155H mutation (p = 0.03).We identified amyotrophic lateral sclerosis (ALS) was diagnosed in 13 individuals (8.9%) and Parkinson's disease in five individuals (3%); however, there was no genotypic correlation. This study represents the largest dataset of patients with VCP disease and expands our understanding of the natural history and provides genotype-phenotype correlations in this unique disease.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22909335      PMCID: PMC3618576          DOI: 10.1111/cge.12000

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  42 in total

Review 1.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.

Authors:  D Neary; J S Snowden; L Gustafson; U Passant; D Stuss; S Black; M Freedman; A Kertesz; P H Robert; M Albert; K Boone; B L Miller; J Cummings; D F Benson
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

2.  A new familial disorder of combined lower motor neuron degeneration and skeletal disorganization.

Authors:  W S Tucker; W H Hubbard; T D Stryker; S W Morgan; O B Evans; F R Freemon; G B Theil
Journal:  Trans Assoc Am Physicians       Date:  1982

3.  Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations.

Authors:  Mark S Forman; Ian R Mackenzie; Nigel J Cairns; Eric Swanson; Philip J Boyer; David A Drachman; Bharati S Jhaveri; Jason H Karlawish; Alan Pestronk; Thomas W Smith; Pang-Hsien Tu; Giles D J Watts; William R Markesbery; Charles D Smith; Virginia E Kimonis
Journal:  J Neuropathol Exp Neurol       Date:  2006-06       Impact factor: 3.685

4.  Mutant valosin-containing protein causes a novel type of frontotemporal dementia.

Authors:  Rolf Schröder; Giles D J Watts; Sarju G Mehta; Bernd O Evert; Petra Broich; Klaus Fliessbach; Katharina Pauls; Volkmar H Hans; Virginia Kimonis; Dietmar R Thal
Journal:  Ann Neurol       Date:  2005-03       Impact factor: 10.422

5.  Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene.

Authors:  D Haubenberger; R E Bittner; S Rauch-Shorny; F Zimprich; C Mannhalter; L Wagner; I Mineva; K Vass; E Auff; A Zimprich
Journal:  Neurology       Date:  2005-10-25       Impact factor: 9.910

6.  Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation.

Authors:  R M Dai; C C Li
Journal:  Nat Cell Biol       Date:  2001-08       Impact factor: 28.824

7.  TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia.

Authors:  C C Weihl; P Temiz; S E Miller; G Watts; C Smith; M Forman; P I Hanson; V Kimonis; A Pestronk
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-10       Impact factor: 10.154

8.  Clinical and genetic heterogeneity in chromosome 9p associated hereditary inclusion body myopathy: exclusion of GNE and three other candidate genes.

Authors:  Giles D J Watts; M Thorne; M J Kovach; A Pestronk; Virginia E Kimonis
Journal:  Neuromuscul Disord       Date:  2003-09       Impact factor: 4.296

9.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.

Authors:  Giles D J Watts; Jill Wymer; Margaret J Kovach; Sarju G Mehta; Steven Mumm; Daniel Darvish; Alan Pestronk; Michael P Whyte; Virginia E Kimonis
Journal:  Nat Genet       Date:  2004-03-21       Impact factor: 38.330

10.  Clinical and molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy and Paget disease of bone.

Authors:  V E Kimonis; M J Kovach; B Waggoner; S Leal; A Salam; L Rimer; K Davis; R Khardori; D Gelber
Journal:  Genet Med       Date:  2000 Jul-Aug       Impact factor: 8.822

View more
  41 in total

1.  Frontotemporal dementia-related gene mutations in clinical dementia patients from a Chinese population.

Authors:  Zhihong Shi; Shuai Liu; Lei Xiang; Ying Wang; Mengyuan Liu; Shuling Liu; Tong Han; Yuying Zhou; Jinhuan Wang; Li Cai; Shuo Gao; Yong Ji
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

2.  Parkinsonism in a patient with valosin-containing protein gene mutation showing: a case report.

Authors:  Motoki Fujimaki; Kazuaki Kanai; Sayaka Funabe; Masashi Takanashi; Kazumasa Yokoyama; Yuanzhe Li; Nobutaka Hattori
Journal:  J Neurol       Date:  2017-03-31       Impact factor: 4.849

Review 3.  Regulation of molecular chaperones through post-translational modifications: decrypting the chaperone code.

Authors:  Philippe Cloutier; Benoit Coulombe
Journal:  Biochim Biophys Acta       Date:  2013-02-28

4.  Cytokine profiling in patients with VCP-associated disease.

Authors:  Eric Dec; Prachi Rana; Veeral Katheria; Rachel Dec; Manaswitha Khare; Angèle Nalbandian; Szu-Yun Leu; Shlomit Radom-Aizik; Katrina Llewellyn; Lbachir BenMohamed; Frank Zaldivar; Virginia Kimonis
Journal:  Clin Transl Sci       Date:  2013-10-03       Impact factor: 4.689

5.  A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene.

Authors:  Jake Plewa; Abhilasha Surampalli; Marie Wencel; Merit Milad; Sandra Donkervoort; Vincent J Caiozzo; Namita Goyal; Tahseen Mozaffar; Virginia Kimonis
Journal:  Neuromuscul Disord       Date:  2018-06-27       Impact factor: 4.296

6.  A case report comparing clinical, imaging and neuropsychological assessment findings in twins discordant for the VCP p.R155C mutation.

Authors:  Abhilasha Surampalli; Brian T Gold; Charles Smith; Rudy J Castellani; Manaswitha Khare; Hon Yu; Celeste Nguyen; Mary Lan; Marie Wencel; Sharon Wigal; Vince Caiozzo; Virginia Kimonis
Journal:  Neuromuscul Disord       Date:  2014-10-22       Impact factor: 4.296

Review 7.  A Brazilian family with inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia linked to the VCP pGly97Glu mutation.

Authors:  Samuel Katsuyuki Shinjo; Sueli Mieko Oba-Shinjo; Antonio Marcondes Lerario; Suely Kazue Nagahashi Marie
Journal:  Clin Rheumatol       Date:  2017-11-10       Impact factor: 2.980

8.  Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy.

Authors:  E Al-Obeidi; S Al-Tahan; A Surampalli; N Goyal; A K Wang; A Hermann; M Omizo; C Smith; T Mozaffar; V Kimonis
Journal:  Clin Genet       Date:  2018-01       Impact factor: 4.438

9.  VCP is essential for mitochondrial quality control by PINK1/Parkin and this function is impaired by VCP mutations.

Authors:  Nam Chul Kim; Emilie Tresse; Regina-Maria Kolaitis; Amandine Molliex; Ruth E Thomas; Nael H Alami; Bo Wang; Aashish Joshi; Rebecca B Smith; Gillian P Ritson; Brett J Winborn; Jennifer Moore; Joo-Yong Lee; Tso-Pang Yao; Leo Pallanck; Mondira Kundu; J Paul Taylor
Journal:  Neuron       Date:  2013-03-14       Impact factor: 17.173

Review 10.  Parkinsonian syndrome in familial frontotemporal dementia.

Authors:  Joanna Siuda; Shinsuke Fujioka; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2014-06-13       Impact factor: 4.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.